• shareshare
  • link
  • cite
  • add
Other research product . Other ORP type . 2018

The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors

Cao, Fangyuan; Zwinderman, Martijn R H; Dekker, Frank J;
Open Access
Published: 02 Mar 2018
Histone deacetylases (HDACs) are epigenetic drug targets that have gained major scientific attention. Inhibition of these important regulatory enzymes is used to treat cancer, and has the potential to treat a host of other diseases. However, currently marketed HDAC inhibitors lack selectivity for the various HDAC isoenzymes. Several studies have shown that HDAC3, in particular, plays an important role in inflammation and degenerative neurological diseases, but the development of selective HDAC3 inhibitors has been challenging. This review provides an up-to-date overview of selective HDAC3 inhibitors, and aims to support the development of novel HDAC3 inhibitors in the future.

Journal Article, Review

Related Organizations
68 references, page 1 of 7

1. Roche, J.; Bertrand, P. Inside HDACs with more selective HDAC inhibitors. Eur. J. Med. Chem. 2016, 121, 451-483. [CrossRef] [PubMed]

2. Wapenaar, H.; van den Bosch, T.; Leus, N.G.J.; van der Wouden, P.E.; Eleftheriadis, N.; Hermans, J.; Hailu, G.S.; Rotili, D.; Mai, A.; Dömling, A.; et al. The relevance of Kicalculation for bi-substrate enzymes illustrated by kinetic evaluation of a novel lysine (K) acetyltransferase 8 inhibitor. Eur. J. Med. Chem. 2017, 136, 480-486. [CrossRef] [PubMed]

3. Hull, E.E.; Montgomery, M.R.; Leyva, K.J. HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases. Biomed. Res. Int. 2016, 2016. [CrossRef] [PubMed]

4. Reid, M.A.; Dai, Z.; Locasale, J.W. The impact of cellular metabolism on chromatin dynamics and epigenetics. Nat. Cell Biol. 2017, 19, 1298-1306. [CrossRef] [PubMed]

5. Clayton, A.L.; Hazzalin, C.A.; Mahadevan, L.C. Enhanced Histone Acetylation and Transcription: A Dynamic Perspective. Mol. Cell 2006, 23, 289-296. [CrossRef] [PubMed] [OpenAIRE]

6. Yang, X.J.; Seto, E. The Rpd3/Hda1 family of lysine deacetylases: From bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 2008, 9, 206-218. [CrossRef] [PubMed]

7. Haberland, M.; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat. Rev. Genet. 2009, 10, 32-42. [CrossRef] [PubMed]

8. Qin, H.-T.; Li, H.-Q.; Liu, F. Selective histone deacetylase small molecule inhibitors: Recent progress and perspectives. Expert Opin. Ther. Pat. 2016, 27, 621-636. [CrossRef] [PubMed]

9. Seto, E.; Yoshida, M. Erasers of histone acetylation: The histone deacetylase enzymes. Cold Spring Harb. Perspect. Biol. 2014, 6. [CrossRef] [PubMed]

10. Vigushin, D.M.; Ali, S.; Pace, P.E.; Mirsaidi, N.; Ito, K.; Adcock, I.; Coombes, R.C. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 2001, 7, 971-976. [CrossRef] [PubMed]

Funded by
NWO| Expanding the molecular toolbox in anti-inflammatory drug discovery
  • Funder: Netherlands Organisation for Scientific Research (NWO) (NWO)
  • Project Code: 2300172468
Novel tools to read and write the epigenetic code in inflammation
  • Funder: European Commission (EC)
  • Project Code: 309782
  • Funding stream: FP7 | SP2 | ERC
Download from
Other ORP type . 2018
Providers: NARCIS